Chemotherapy by Infusion for Malignant Bone Tumors

  • F. R. Eilber
  • J. Mirra
  • J. Eckardt
  • E. Caulkins
Conference paper


One of the important factors for determining the destruction of human cancer cells by chemotherapeutic agents is the proliferative state of the tumor cell population at the time of drug exposure. Two classes of chemotherapeutic agents are available: one is nonspecific or cell-cycle specific; the second is phase specific (Valeriote and Von Pulten, 1975). Phase-specific agents kill cells in one phase of the cell cycle and have little effect on cells in other phases, whereas cell cycle specific agents kill cells throughout the cell cycle and are less cytotoxic to cells in the nonproliferative state. These differences in cell··cycle kinetics are responsible for the differences in tumor response to various anticancer agents. For example, little or no response would be noted with a cell cycle specific drug in a tumor with a large fraction of cells in the resting or G0 phase (low grade or mitotically inactive tumors). If the drug were administered frequently, however, or if the exposure were prolonged, then more normal hemopoietic stem cells would be destroyed, causing increasing toxicity and intolerable side effects to nonmalignant cells that would be mitotically active.


Limb Salvage Superficial Femoral Artery Malignant Bone Tumor Isolate Limb Perfusion Local Tumor Recurrence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Benjamin, R., Hegha, H., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S., Blumenschein, G., and Freireich, E.: Reduction of adriamycin cardiac toxicity using a prolonged continuous intravenous infusion. Proc. AACR 22, 179, 1981.Google Scholar
  2. 2.
    Bristow, M.R., Billingham, M.E., Menson, J., and Daniels, J.R.: Clinical spectrum of anthacyline antibiotic cardiotoxicity. Cancer Treat. Rep. 62, 873, 1978.PubMedGoogle Scholar
  3. 3.
    Didolkar, M., Kanter, P., Boffi, R., Swartz, H., Lopez, R., and Baez, N.: Comparison of regional versus systemic chemotherapy with adriamycin. Ann. Surg. 187, 332, 1978.PubMedCrossRefGoogle Scholar
  4. 4.
    Greco, F., Brereton, H., Kent, H., Zimbler, H., Merril, J·., and Johnson, R.: Adriamycin and enhanced radiation reaction in normal esophagus and skin. Ann. Int. Med. 85, 294, 1976.PubMedGoogle Scholar
  5. 5.
    Haskell, C.M., Silverstein, M., Rangel, D., Hunt, J., Sparks, F., and Morton, D.L.: Multimodality cancer therapy in man: A pilot study of adriamycin by arterial infusion. Cancer 33, 1485, 1974.CrossRefGoogle Scholar
  6. 6.
    Jaffe, N., Chuang, V., Wallace, S., Ayala, A., Murray, J., Romsdahl, M., and Benjamin, R.: Osteosarcoma: Control of the primary tumor with intraarterial cisplatinum. Proc. AACR 21, 197, 1980.Google Scholar
  7. 7.
    Kraybill, W., Harrison, M., Sasaki, T. and Fletcher, W.: Regional intra-arterial infusion of adriamycin in the treatment of cancer. Surg. Gynecol. Obstet. 144, 335, 1977.PubMedGoogle Scholar
  8. 8.
    Lokich, J., Bothe, A., Zipoli, T., Green, R., Somneborn, H., Paul, S. and Philips, T.: Constant infusion schedule for adriamycin: A phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. J. Clin. Oncol. 1., 24, 1983.PubMedGoogle Scholar
  9. 9.
    Mavligit, G., Benjamin, R., Pratt, Y., Jaffe, N., Chuang, V., Wallace, S., Murray, J., Ayala, A., Johnston, S., Hersh, E., and Calvo, D.: Intraarterial cis-platinum for patients with inoperable skeletal tumors. Cancer 48, 1, 1981.PubMedCrossRefGoogle Scholar
  10. 10.
    Pratt, Y.: Intraarterial chemotherapy in cancer treatment—selected abstracts. International Cancer Research Databank Program. National Cancer Institute, U.S. Department of Health and Health Services, September 1982.Google Scholar
  11. 11.
    Rosen, G., Caparros, B., Huvos, A., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R., Lane, J.J. and Metha, B.: Preoperative chemotherapy for osteosarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to chemotherapy. Cancer 49, 1221, 1982.PubMedCrossRefGoogle Scholar
  12. 12.
    Rudolph, R., Stein, R., and Pattillo, R.: Skin ulcers due to adriamycin. Cancer 38, 1087, 1976.PubMedCrossRefGoogle Scholar
  13. 13.
    Stehlin, J.S., De Ipolyi, P., Giovanella, B.C., Gutierrez, A., and Anderson, R.F.: Soft tissue sarcomas of the extremity: Multidiscipllnary therapy employing hyperthermic perfusion. Am. J. Surg. 130, 64, 1975.CrossRefGoogle Scholar
  14. 14.
    Valeriote, F., and Van Pulten, L.: Proliferation-dependent cytotoxicity of anticancer agents: A review. Cancer Res. 35, 2619, 1975.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • F. R. Eilber
  • J. Mirra
  • J. Eckardt
  • E. Caulkins

There are no affiliations available

Personalised recommendations